Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk’s Hemophilia B Drug Faces Safety Scrutiny By US FDA Panel

Executive Summary

Novo’s long-acting coagulation Factor IX showed polyethylene glycol (PEG) accumulation in the choroid plexus of animals, potentially raising a neurological safety issue when used in humans, FDA says ahead of Blood Products Advisory Committee review.

You may also be interested in...



Novo Nordisk Gets Approval For Hemophilia B Treatment Sans Postmarketing Requirements

Rebinyn's approval without postmarketing requirements comes as a surprise, given the advisory committee's concerns that the proposed plans weren't robust enough, as well as concerns from FDA about the treatment's safety.

Novo Hemophilia Drug's Postmarket Monitoring Plan Not Robust Enough – US Panel

FDA advisory committee members support approval of investigational hemophilia B treatment nonacog beta pegol but say Novo Nordisk needs more systematic approach to monitoring for neurological and developmental adverse events.

CHMP’s March Recommendations Include Dinutuximab, Nonacog Beta Pegol And Trumenba

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) meets monthly to review applications for centralized EU marketing authorization. Here’s a summary of their March 2017 recommendations.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel